Clinical trial
Tuberculosis Prevention for HIV Infected Adults
NCT00057122 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT00057122 |
|---|---|
| Title | Tuberculosis Prevention for HIV Infected Adults |
| Official title | Novel TB Prevention Regimens for HIV-Infected Adults |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | HIV Infections, Tuberculosis |
| Intervention type | Drug |
| Interventions | Isoniazid, Rifapentine, Rifampin |
| Enrollment | 1,148 |
| Start date | Sep 1, 2002 |
| Primary completion | Nov 1, 2008 |
| Completion | Jun 1, 2009 |
| First posted | Mar 28, 2003 |
| Last update posted | Oct 22, 2012 |
| Countries | South Africa |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: